根治性立体定向消融放疗(SABR)治疗头颈部鳞状细胞癌(HNSCC)肺寡转移:一项多中心回顾性研究
这项多中心回顾性研究评估了SABR治疗HNSCC异时性孤立肺寡转移的疗效,纳入2007年11月至2018年2月间52例患者,中位随访45.3个月,1年和2年总生存率分别为85.8%和65.9%,中位总生存46.8个月,仅1例(1.9%)出现≥3级毒性。作者认为在经选择的转移性HNSCC患者中,早期发现并用SABR治疗肺转移是有效且安全的,但需前瞻性研究验证。
要点
- SABR治疗HNSCC异时性肺寡转移后,1年和2年总生存率分别为85.8%和65.9%,中位总生存46.8个月。
- 中位随访45.3个月时,粗局部控制率和粗转移控制率分别为74%和38%。
- 治疗耐受良好,仅1例(1.9%)报告≥3级毒性。
核心结论
- 在经选择的转移性HNSCC患者中,早期发现并用SABR治疗肺转移是有效且安全的;需要前瞻性研究来验证这一潜在转变。
研究设计与样本
- 多中心回顾性研究,纳入2007年11月至2018年2月间52例接受SABR治疗的HNSCC异时性肺转移患者,SABR适应证经多学科肿瘤委员会审核,所有患者SABR后接受CT或PET CT监测。
诊断标准与关键数值
- 入选条件为与HNSCC转移一致的孤立性1个或2个肺部病灶(<5cm)。
- 绝大多数患者(94.2%)接受60 Gy分3次照射。
- 41例(78.5%)为单发肺转移,11例(21.5%)为2个肺转移。
- 1年和2年总生存率分别为85.8%和65.9%,中位总生存46.8个月。
- 中位随访45.3个月时,粗局部控制率和粗转移控制率分别为74%和38%。
临床应用与阅片要点
- SABR后采用CT或PET CT进行监测。
- 约四分之一患者因远处肺复发再次接受SABR治疗。
- 仅1例(1.9%)报告≥3级毒性。
局限性
- 原文为回顾性研究。
- 需要前瞻性研究来验证这一潜在转变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this retrospective study was to assess outcomes of SABR for metachronous isolated lung oligometastases from HNSCC.
METHODS: For patients who developed isolated, 1 or 2 lungs lesions (<5cm) consistent with metastases from HNSCC, the indication of SABR was validated in a multidisciplinary tumor board. All patients were monitored by CT or PET CT after SABR (Stereotactic Ablative Body Radiation) for HNSCC.
RESULTS: Between November 2007 and February 2018, 52 patients were treated with SABR for metachronous lung metastases. The median time from the treatment of the primary HNSCC to the development of lung metastases was 18 months (3-93). The cohort's median age was 65.5 years old (50-83). The vast majority (94.2%) received 60 Gy in three fractions. Forty-one patients (78.5%) presented a solitary lung metastasis, while 11 patients (21.5%) had two lung metastases. With a median follow-up of 45.3 months, crude local and metastatic control rates were 74 and 38%, respectively. 1 year and 2 year Overall Survival (OS) were 85.8 and 65.9%, respectively. The median OS was 46.8 months. About one-fourth of patients were retreated by SABR for distant pulmonary recurrence. The treatment was well tolerated with only one patient who reported ≥ grade 3 toxicity (1.9%).
CONCLUSION: In selected metastatic HNSCC patients, early detection and treatment of lung metastases with SABR is effective and safe. Prospective studies are required to validate this potential shift.
ADVANCES IN KNOWLEDGE: Patients with oligometastases and controlled primary HNSCC seem to benefit from metastasis directed therapies.
引用
- Debbi, Loganadane, To, et al. Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study. Br J Radiol. 2022. PMID: 35143326. doi:10.1259/bjr.20210033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。